The end of "sales with gold"! On behalf of the record A large number of pharmaceutical people are afraid of being eliminated

Medical network December 9 - Medical reform continues to deepen, policies and regulations accelerated release, industry rules remodeled, a large number of pharmaceutical people are afraid of being eliminated.
Pharmaceutical representatives for the record, the value of the pharmaceutical industry further remodeled from December 1, "Pharmaceutical representatives filing management measures (trial)" (referred to as the "record measures") formally implemented, medical institutions may not allow unfiled pharmaceutical representatives to the medical personnel, pharmaceutical personnel of the institution to carry out academic promotion and other activities.
recently held the "20th China Pharmacist Week" meeting, the State Drug Administration, the head of the Drug Supervision and Administration Department also carried out an authoritative interpretation of the record.
for the competent departments promulgated by the "pharmaceutical representative filing management measures", an enterprise LT member said: "About the 'pharmaceutical representative filing' has been carried out for many years, implementation is difficult."
this time should also be thunder, rain is small, finally can not.
believe that the medical people who hold this view are not in the minority, after all, our pharmaceutical representative group is too large, really effective management is more difficult.
Indeed, from the pharmaceutical representative filing platform registration page shows that in the "domestic drug market licensing holders" column, the choice of pharmaceutical companies only 7 pharmaceutical companies, and "overseas drug market licensing holders" column, dozens of pharmaceutical companies have reported.
foreign pharmaceutical companies are better than domestic pharmaceutical companies in terms of ideas and actions;
The Filing Measures require that pharmaceutical representatives need to have a high level of medical expertise, familiar with product characteristics, through communication with doctors, access to product use efficacy, adverse reactions and other information, and thus help holders to implement drug alert management norms, continuously improve the quality of drugs, to achieve the full life cycle management of drugs.
This will require pharmaceutical representatives to have a certain medical or pharmacy expertise, in their dealings with health care personnel, based on medical and pharmaceutical value exchange, so as to provide the right methods of drug use, to help medical practitioners reasonable prescription drugs, to avoid drug abuse.
, it is also required that pharmaceutical manufacturers will change the pharmaceutical marketing model, from the low-value exchange model to the high-value medical application model.
Pharmaceutical industry is already a high threshold industry, the majority of past pharmaceutical representatives played a sales role, responsible for sales performance appraisal, the current pharmaceutical representative record management measures clearly stipulate that pharmaceutical representatives will not be able to undertake the task of drug sales, the main responsibility is to formulate pharmaceutical product promotion plans and programs;
this is bound to the professional requirements and capacity requirements of pharmaceutical representatives to further raise the threshold.
continues to deepen, China Pharmaceuticals from low-value to high-value conversion of many innovative pharmaceutical companies to the corporate mission to treat unseeded disease needs, and make innovative drugs more patients to use.
has become the norm in Europe and the United States, but China's innovative pharmaceutical companies are just getting started.
With the deepening of medical reform, new drug research and development, clinical, registration and other policy support, overseas scientists began to return home tide, according to incomplete statistics, after 2013 about 250,000 high-tech talent returned home, a large part of which belongs to the biopharmaceutical field.
in the wave of return to China, some returned with a team, some with scientific research results, including scientists from the start.
According to incomplete statistics, by the end of 2019, there were more than 100 pharmaceutical enterprises with innovative drug projects, and some innovative pharmaceutical enterprises were newly established in recent years, which is one of the important achievements of the national talent strategy.
Chinese innovative drugs started late, with me-too-based, some me-better, and now there's a gradual first-in-class.
The field of cancer treatment is developing relatively fast, according to relevant data, as of January 2020, China has a total of 821 anti-cancer drugs at different stages of clinical development, including 404 me-too and 359 first-in-class (FIC) drugs, FIC drugs accounted for nearly half, especially in the field of immuno-tumor more prominent.
, there are only people and projects that are not enough to revitalize the pharmaceutical industry, and there needs to be a stage, a platform, and space to operate.
present, generic pharmaceutical industry enterprises are still the mainstream, year-on-year policy dividends, accumulated harm for a long time, most generic pharmaceutical enterprises difficult to consciously, automatic transformation.
, cage-for-bird exchange requires accelerating the introduction of generic drugs through "tangible hands" and replacing generics with innovative ones to promote the development of innovative drugs.
Recently, Shandong collection of drugs to reduce the price of 98%, the pharmaceutical media continued to rebound, "this is to buy medicine to send bottles, or buy bottles to send drugs cry," "the highest price reduction of 98.5%, experts said a hair did not rise."
" collection is becoming more and more intense, a wider range, speed up, on the one hand, the reform of the policy authorities landed, on the other hand, the concept of medical people has not changed, the gap between the two will produce such a voice.
, compared with generic drugs, are still low-value products, the world is no exception.
20 percent of sales of innovative drugs in the U.S. and only 20 percent of generics in 80 percent, which is in line with economic theory that prices fluctuate around value and low values should be low.
different from the old times, but also the meaning behind the low value is also different.
the early days, the country waste to be developed, the pharmaceutical industry is in the 0 foundation, if you can imitate foreign original research drugs, for clinical treatment, it is inexplorable.
With the economic development, especially in the mid-to-late 1990s, a large number of foreign pharmaceutical companies entered China to invest in factories, to a certain extent to meet the treatment needs of Chinese patients at the same time, on the other hand, also to China's generic pharmaceutical companies to provide a "lazy" excuse.
generic drug companies selling low-value generic drugs at high prices has become the main source of income for Chinese pharmaceutical companies, and generic drug sales models have become the norm, hindering the development of innovative drugs.
2019, the health care reform authorities with "planned hands" to speed up the "cage for birds", the launch of the National Health Insurance Fund strategic purchase.
the results of the 2019 4-plus-7 results were announced, the vast number of medical people rushed to tell each other, all over the city of blood, exclaiming at the sharp decline in prices, the price results far below market expectations.
Today, after 2 years and 4 national drug collection (three rounds), many provincial drug collection baptism, the medical people began to realize that behind the price reduction is the rapid development of China's pharmaceutical industry rigid demand, from low value to high value conversion.
industry transformation, Tenglong for birds, do not retreat with the country's pharmaceutical industry continued in-depth reform, the pharmaceutical industry will continue to optimize the ecological environment, remodel the food chain, low-value and low-scientific content links will need to be optimized, so as to directly promote the pharmaceutical industry cage for birds, in exchange for high-value drugs, which is not only to free up drugs, pharmaceutical practitioners, especially pharmaceutical representatives have new high requirements, or a remodeling of pharmaceutical representatives, or even directly eliminate a group of unqualified pharmaceutical representatives.
May 28, 2018, the leaders of the state at the 19th Congress of academicians of the Chinese Academy of Sciences, the 14th Congress of academicians of the Chinese Academy of Engineering, said, "To aim at the forefront of science and technology in the world, seize the general trend, play a good "first hand chess", lay a good foundation, reserve long-term, willing to sit on the cold bench, the courage to be tree-planters, diggers, to achieve forward-looking basic research, leading the foundation of the original achievements of the world's scientific and technological power.
" in the field of medicine is no exception, advocating scientific and technological innovation to promote the upgrading of the pharmaceutical industry, we must take the lead in science and technology, to ensure the global leadership of innovative drugs.
as of December 31, 2018, there were 24 companies involved in the Sino-American double report, with a total of 44 varieties, which will form a "first hand chess" of "innovative drugs" to some extent, according to reports.
Since the direction of policy advocacy has been clear, discarding low value in order to "free up cages for birds", in addition to freeing up "generic drugs", from the "medical representative for the record" of the implementation of the management approach, is a hidden way to "free up" people.
If this program can be implemented, the Chinese pharmaceutical enterprise operating model is some kind of promotion, "high-value representatives" and "high-value marketing" will replace "low-value representatives" and "fees", and pharmaceutical representatives will no longer be equivalent to sales staff, but become a sophisticated academic promotion staff with high-level expertise, become a long-term or even life-long professional career.
A survey of 2,854 professional pharmaceutical salespeopeoes found that most pharmaceutical representatives in the United States see work as a long-term career, with 54 percent having 6 to 20 years of work experience, 70 percent between the ages of 31 and 50, and 16 percent between the ages of 50 and 60.
can not only be done for a long time, but also at a very old age.
pharmaceutical industry, with the remodeling of the industry, pharmaceutical representatives will also usher in the second spring, to achieve innovative drugs and "high-value marketing" prevailing, mutual benefit and win-win situation.
。